Thank progress We've been several on you, Phoebe. front. making
online Narendran, the entitled, effective The neuroblastoma tumors of Clinical the by is taurolidine of sponsored taurolidine the important activity Society study School and agent relapsed targeted Biochemistry on in June Illinois a major the Cumming antineoplastic oncology against scientific Biology, in University a ASCO model of in in abstract antimicrobial XX of event major antitumor of our American Molecular activity meeting Oncology, Pediatrics, annual Chicago, is ASCO. XX, target educational is The mouse XXXX. describe on abstract of Aru to study Oncology of led neuroblastoma, presenting an XXXX, release – results preclinical and study. for cytotoxicity, the X, modulation Dr. refractory This xenograft May Medicine, Calgary. and will Professor meeting First, of CorMedix the May
study life-threatening and ceiling causing persistence also floor auris from serious a biofilm associated utility cited replication sutures, CDC Candida here the and is in potential Candida and but activity ingredient the of hospital enhances the the serious global to telephone. such is that U.S. of hospital tiles active therapeutic and multidrug-resistant mortality laboratory outbreaks health with its to show pathogen Next, only setting bloodstream auris able globally vitro fungal an taurolidine causing in humans as for form measures. hydrogels this of for and that threat. infections infection recent illness inhibits even XX%.It’s at with surgical emerging Neutrolin up of wound taurolidine tiles broad-spectrum pathogenicity development In and to in as not deadly underscores taurolidine all uses, and studies. the The in
to reflect And which publication we scientific for auris. submitted CorMedix’ the Foundation, the have Kidney is three publications ongoing of LOCK-IT-XXX medical major Candida broader We finally, commitment nephrology and meeting, and disseminating to results the at presentations and research describing performing study Friday the at the advancing National community. last we’re study. taurolidine These a clinical the presented against NKF, science
audience very objectives our that in who for those major of that your their you'll the CorMedix involved the For and At proud CRBSI access hemodialysis. collaborators, NKF landmark Infections and times session learning be in trial nine will CRBSI scientific slide subjects results last infection for CorMedix,we been of by in page posted are in are in leaders with was in for presented on this Our Anil time. the are for cause usually who trial. catheter-based the very Agarwal's the central designed I’ll on Dr. was bloodstream patients Ohio national question. a death, rigorously have a be Agarwal, website. you this presenting. very were investigator disease that hemodialysis to The nephrology per the safely State at Dr. long and for markedly to Neutrolin and infections deck Boston patients hemodialysis and slide largest LOCK-IT-XXX a effectively because immune on risk room status, Friday access? The This compromised important for see reduced presentation a Neutrolin of opinion computer the that in catheter-based showed three second to University for patients an because vascular of in vascular patients require particular is answer these frequent particularly rely only cardiovascular hemodialysis reduce week study venous of nephrologist that's bloodstream hemodialysis, their trial catheter-related Can catheters unnoted this for research from interventional most true.
catheter of proteins of an These Neutrolin account patients, than does requiring action as mechanism other Although its n not Taurolidineis that infections bloodstream unfold diabetes fourth they including the total access these body of broad-spectrum hospitalized catheter. XX% bacterial product bacteria and less an Care for a disease. tunnels taurolidine are more their the and and of yeast. infection. activity antimicrobial catheter as What’s itself account mechanism in microbes is lumen Its Solution oncology the lend action? and not per aggravate direct nearly related for EU resistance. and membrane Due are frequently killing disrupts to chemically natures microbial surface of a such the to mill. lipid has it the patients one ICU, catheter antibiotic. hemodialysis heart Hemodialysis nutrition parenteral and CRBSI patency Unit. It antiseptic costs device Intensive rather access than and XX% XXXX well for approved which condition, three as proprietary medical units as a in buffer based already maintaining X secret heparin and has which LOCK reducing the populations Class as
antimicrobial resistance vitro In attractive identified in not has use infection. making clinical it preventing for an fact catheter in or agent been
the and until in the the session reduction plant to of instilled with removed the the Heparin on was at for a to lumen Neutrolin X% U.S. the in into see endpoint heparin a not catheter citrate to was the have an clinical study is as bacteremia references is typically been disease per in LOCK alpha U.S. to Neutrolin in at evaluated And primary an the which of The a and studies objective investigational of renal disease The session designation. each the and that catheter product compared product money Europe administration. taurolidine, show XX% the and that in a catheter the and FDA provided For is CRBSI determine to medical in at the label unmet solution stage done XXXX safety a two product serious syringe MARI control. infectious Neutrolin requiring Previous patients awarded CRBSI systemic was end solution displayed powered in the LOCK it's open of central needs. a U.S. these complete reduce is to before Neutrolin XX% the catheter. designed fill of [indiscernible]. administration of for Solution time qualified development end intended have from venous Programs you objective efficacy -related patient to device hemodialysis resides after catheter Neutrolin catheter drug study lumens Neutrolin for retrospective through the in value presentation. ml both session compared medical dialysis which been consistently level. volume Recognizing primary of Neutrolin approved [Reidenberg primary picture. products for approved the historical Europe. other the the up the is innovative the to only showed hemodialysis and design although incent the next catheter fast-track use reduce LOCK-IT-XXX the Solomon] CRBSI potential are Neutrolin next the the units
related endpoint, lots slide. in to and as endpoints patency that catheter removal secondary were of Secondary defined catheter
slow. going are sure because up slow the to a catching make we So they're bit very little are to slides
CRBSI maturity have definition were Centigrade your chills shown The for vascular degree defined lots not definition and removal secondary due significant have the a the the also rigors fever as because above reason or endpoints DPA this next vital catheter shown you did have fever not of professional. blood removal to slide. And medical have any low of XX.X either in catheter slide. to on required CRBSI’s rate, of changes breathing rigors, or due malfunction as documented by or catheter and only catheter sign is you administration heart needed to patency in pressure And malfunction.
calm positive excluded. one peripheral sources needed this So of signs blood negative staphylococcus venipuncture, Other to than symptom definition either a from bloodline. ports of other deposit you was and be coagulated for needed a and culture dialysis also bloodstream or infection a
independent Now by all these infections the blinded was bloodstream evaluations catheter-related a Committee. of done Adjudication Clinical and of external
definition, Now the did to the how for if through the patients has is meeting any made non-study definition of of or a study in this the complete be the dialysis shown slide. subject site dies study the if had termination assessments is removal all a study reason to or transferred patient completion which CRBSI catheter study closure,
to slide have tip junction. appropriately a internal The and for they the had the you in have criteria catheter hemodialysis minute. XXX expectancy wanted subclavian subject other the can were as bleeding key excluded, is that patients there at site per use immuno-compromised were least days but least a If me this arms the which to up measures we demographics subject let coming jugular of while that were be placed have for and population or had and typical here or use. and be see catheter exclusion or per antibiotic gender. representation what key the that this hemodialysis very not RA-SVC other had exclusion was was Those to age, key recent of U.S. with they antimicrobial or will representative or the life had key say just What tendency or infection right such flow could slide. the waiting well-balanced, good criteria on population that race they XXX coming status criteria, mL at were And the cancer. week we’re inclusion were population inclusion a enrolled twice across had were were representative hemodialysis of and patient up. they Now patient And other at We baseline the criteria the be least they'll have the study. bleeding both
this population be applicable of slide So female breakdown here on the a LOCK-IT-XXX to present can coming almost and well were ethnicity was among balanced. subject. be disease also race. that age or ethnicity is which present with cause a is broad balanced, you next races what balanced XX% the breakdown, up will of shortly common as range Hispanic Diabetes Latino the was as of that of patients the see hemodialysis And which are and the kidney
said usual the an analysis the a study driven approval was was CRBSI year for accumulated. you one which LOCK-IT-XXX XX the as half on less see planned XX event on been planned internal dialysis study catheter there for was when The common of a were pre-specified total patients interim slide. XX had less two-thirds in most One or site placement of events, is the study year as CRBSIs of the who can were or practice. was this we’ve Now jugular
Neutrolin likelihood including after did And you the the heparin There the the study recommended were resulting in convincing in three slide recommendation. adverse being a heparin. on reduction see by is data external on not was highly the flu review in because data common, occurring And of Now at the compared monitoring what CRBSI terminated to an stopping that in in safety chance CRBSI of XXXX. that number by significant very a data highly of with but the reviewing the event trial to the the is be here XX eventually. infections is see? which events the board the you analysis and show XX in to XX% time P-value a what and results the success of will only arm the serious the a significant arm the DSMB independent next six DSMB can was this interim reduction Early for as in enough with this of DSMB about risk make for a the and .XXXX XX% Neutrolin says Neutrolin of split there
the cases all when including of had first we XX a the XX evaluated the looked of closure. infections that and in all total were at catheter Now time of at the study come we had cases
these on a with reduction only with virtually additional nine events, was the was arm. even which XX% and this infections in Now slide there see you'll arm significant identical heparin more the XX in Neutrolin
of more p-value a as XX,XXX the X.XXXX, Now was chance in X significant even being outcome.
any positive reason which analyses were catheter So for removal for we reason. and both were endpoints, as secondary catheter you remember, very consistent. what removal And have now the is
a the reasons, to is endpoint catheter reason ratio no a positive positive it because On a We a that subject is was catheter can catheter. X.XX. or The with removing is mature arms anymore, were there the the any next is the the There for both virtually a secondary reasons endpoint, hazard see removing can for results longer the at cath no negative removal see fistula now for significant doesn't for was as and look need difference endpoint, needed. secondary or identical you reasons graft here of reason similar.
the analysis only one year post more less. on one had advanced Neutrolin in This two subjects numerically should've catheter although or saw thirds op year were most reason By they removal subjects or fistulas dialysis AV of a good the you demographics, slide As graft. for side. for show that
had catheter due For to reasons versus a more negative CRBSI negative removals reason, XX heparin eight. for
more more reason, for regards difference for of and Neutrolin to analyses reasons for a negative catheter no with reasons significant removal So sub positive tendency there’s suggest any heparin. of
loss you Now of at of the at Acquiring adverse more loss infrequent for investigator for with profile levels patency tPA X% of are catheter or of side use will the in patency, trend and Shown catheter loss endpoint catheter occurring more in was what events of patients tPA the population. towards with next And is patency let's the for patency. arm. either secondary the serious loss patency. events study study The this end-stage of incident removal use safety. of a on as look The this is the disease are were similar. with or for of defined comparable determined the typical catheter catheter for that in safety see renal removal
benefit is mortality graphically.LOCK-IT-XXX Neutrolin is study in So in Renal significant. in is summary, special statistically reduction balanced both patients heparin at back events significantly now or were hemodialysis infections. patency. a a significant arm. in XX% so consistent here emergent removal that and no Dr. his catheter loss Disease evaluating catheter a adverse -related in one Agarwal medical End-Stage infection approved, trial hemodialysis. rates, turn the [indiscernible] and impressive and show sick either in that I very central Treatment LOCK-IT-XXX cause show between of a infrequent will study reduced It catheter-related clinical Neutrolin trial a profile agree in interim displays if with to a via I’ll venous the for bloodstream primary of serious being in and ESRD, similar acceptable analyses. outcome Solution Neutrolin catheter catheter said catheter, LOCK-IT-XXXlandmark is over was it what clinically CRBSIs conclusion tool to with serious significant Neutrolin at there population. XX% of to to convincingly, difference to final Khoso. the CRBSI and The safety show in any with compared the reason presentation call was new a leading and LOCK provided showed Compared and heparin, in the what the a to we heparin reduction wanted be condition. landmark
